MediPharm Labs Corp.
MEDIF
$0.05
$0.00-2.70%
OTC PK
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -14.40% | -7.76% | 15.70% | 12.83% | 3.89% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -14.40% | -7.76% | 15.70% | 12.83% | 3.89% |
| Cost of Revenue | -5.48% | -21.08% | 33.94% | 23.24% | -15.44% |
| Gross Profit | -26.28% | 36.09% | -21.60% | -6.85% | 49.39% |
| SG&A Expenses | -14.38% | 1.22% | -18.33% | 19.43% | -24.33% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 98.79% | 117.81% | -17.20% | -334.02% | 16.16% |
| Total Operating Expenses | -8.62% | -12.40% | 8.93% | 20.64% | -19.67% |
| Operating Income | -133.67% | 44.39% | 16.60% | -54.15% | 87.79% |
| Income Before Tax | -131.18% | -14.49% | 23.53% | -44.34% | 89.93% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -131.18% | -14.49% | 23.53% | -44.34% | 89.93% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -131.18% | -14.49% | 23.53% | -44.34% | 89.93% |
| EBIT | -133.67% | 44.39% | 16.60% | -54.15% | 87.79% |
| EBITDA | -4,457.14% | 53.42% | 15.40% | -97.04% | 99.49% |
| EPS Basic | -150.00% | -10.00% | 24.49% | -40.43% | 90.91% |
| Normalized Basic EPS | -125.00% | 44.44% | 23.33% | -51.85% | 89.47% |
| EPS Diluted | -150.00% | -10.00% | 24.49% | -40.43% | 90.91% |
| Normalized Diluted EPS | -125.00% | 44.44% | 23.33% | -51.85% | 89.47% |
| Average Basic Shares Outstanding | 2.35% | 2.40% | 2.36% | 2.61% | 2.83% |
| Average Diluted Shares Outstanding | 2.35% | 2.40% | 2.36% | 2.61% | 2.83% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |